When nanomedicines meet tropical diseases

• Eder Lilia Romero,
• Katrien Van Bocxlaer and
• Fabio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 830–832, doi:10.3762/bjnano.15.69

• article collection. Among the articles, an interesting strategy to improve the bioavailability of benzonidazole towards Chagas disease has been presented by Muraca and colleagues, who reported a stable and safe nanostructured lipid formulation with potential effects against Trypanosoma cruzi [2]. In turn

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• still required regarding a realistic use of nanomedicines effective against CD. Keywords: benznidazole; liposomes; nanocrystals; nanomedicines; nanoparticles; Trypanosoma cruzi; Introduction Nanomedicines are used to solve the problems posed by poor solubility and/or permeability and high toxicity of

• nanomedicines against CD will be critically analyzed. Review Chagas disease, a threat no longer limited to developing countries Chagas disease is a parasitic, systemic, chronic, and often fatal infection caused by the protozoan Trypanosoma cruzi [4]. The World Health Organization classifies CD as the most

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• in the chronic stage, possibly because current treatment regimens do not eradicate transiently dormant Trypanosoma cruzi amastigotes. Nanostructured lipid carriers (NLC) appear to be a promising approach for delivering pharmaceutical active ingredients as they can have a positive impact on

• . These results show potential for the development of new nanomedicines against T. cruzi. Keywords: benznidazole; biopharmaceutical study; Chagas disease; nanoparticles; nanostructured lipid carriers; physicochemical characterization; Trypanosoma cruzi; Introduction Chagas disease is a neglected disease

• ]. It is caused by the hemoflagellate protozoan Trypanosoma cruzi, whose life cycle involves transitioning from non-flagellated multiplicative intracellular forms (amastigotes) to blood-circulating non-multiplicative forms (trypomastigotes). It is mainly transmitted by an insect vector of the